Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system

Frontiers in Psychiatry

Volumn 5, Issue APR, 2014, Pages

  Gruber, Oliver ^a   Santuccione, Antonella Chadha ^b   Aach, Helmut ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Cognitive deficits; Glutamate; Negative symptoms; Neuroimaging biomarkers; Schizophrenia; Stratified therapy

Indexed keywords

CYCLOSERINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; SARCOSINE;

BRAIN MAPPING; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; EMOTIONALITY; EPISODIC MEMORY; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; MENTAL DISEASE; NEGATIVE SYNDROME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; VENTRAL TEGMENTUM;

EID: 84901021433     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00032     Document Type: Review

References (146)

1. Insel TR, Wang PS. Rethinking mental illness. JAMA (2010) 303(19):1970-1. doi: 10.1001/jama.2010.555.
2. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature (2010) 468(7321):194-202. doi:10.1038/nature09569.
3. Gruber O, Falkai P. Von der Identifizierung neurofunktioneller Systeme zur Individualisierung der Therapie schizophrener Störungen. Nervenarzt (2009) 80:12-8. doi:10.1007/s00115-008-2615-y.
4. Gruber O. Hirnbild gebungsmarker. Nervenarzt (2011) 82:1404-13. doi:10.1007/s00115-011-3347-y.
5. Insel TR, Cuthbert BN. Endophenotypes: bridging genomic complexity and disorder heterogeneity. Biol Psychiatry (2009) 66(11):988-9. doi:10.1016/j.biopsych.2009.10.008.
6. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry (2010) 167(7):748-51. doi:10.1176/appi.ajp.2010.09091379.
7. Insel TR. Rethinking schizophrenia. Nature (2010) 468(7321):187-93. doi:10.1038/nature09552.
8. Gruber O, Gruber E, Falkai P. Neural correlates of working memory deficits in schizophrenic patients. Ways to establish neurocognitive endophenotypes of psychiatric disorders. Radiologe (2005) 45(2):153-60.
9. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 153:321-30.
10. Green MF, Kern RS, BraffDL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull (2000) 26:119-36. doi:10.1093/oxfordjournals.schbul.a033430.
11. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res (2004) 72:41-51. doi:10.1016/j.schres.2004.09.009.
12. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1-and 4-year prospective study. Schizophr Bull (2005) 31:167-74. doi:10.1093/schbul/sbi004.
13. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry (1994) 151:351-6.
14. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry (2001) 58:165-71. doi:10.1001/archpsyc.58.2.165.
15. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses (2010) 4:189-200. doi:10.3371/CSRP.4.3.6.
16. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry (2008) 165:579-87. doi:10.1176/appi.ajp.2008.07081242.
17. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry (2000) 157:549-59. doi:10.1176/appi.ajp.157.4.549.
18. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology (2012) 37:4-15. doi:10.1038/npp.2011.181.
19. Suzuki M, Yuasa S, Minabe Y, Murata M, Kurachi M. Left superior temporal blood flow increases in schizophrenic and schizophreniform patients with auditory hallucination: a longitudinal case study using 123I-IMP SPECT. Eur Arch Psychiatry Clin Neurosci (1993) 242(5):257-61. doi:10.1007/BF02190383.
20. Dierks T, Linden DE, Jandl M, Formisano E, Goebel R, Lanfermann H, et al. Activation of Heschl's gyrus during auditory hallucinations. Neuron (1999) 22(3):615-21. doi:10.1016/S0896-6273(00)80715-1.
21. Lennox BR, Park SBG, Medley I, Morris PG, Jones PB. The functional anatomy of auditory hallucinations in schizophrenia. Psychiatry Res (2000) 100:13-20. doi:10.1016/S0925-4927(00)00068-8.
22. Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry (2011) 168:73-81. doi:10.1176/appi.ajp.2010.09101522.
23. Kühn S, Gallinat J. Quantitative meta-analysis on state and trait aspects of auditory verbal hallucinations in schizophrenia. Schizophr Bull (2012) 38:779-86. doi:10.1093/schbul/sbq152.
24. Goghari VM, Sponheim SR, MacDonald AW. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev (2010) 34:468-86. doi:10.1016/j.neubiorev.2009.09.004.
25. Andreasen NC, Olsen S. Negative vs positive schizophrenia. Definition and validation. Arch Gen Psychiatry (1982) 39:789-94. doi:10.1001/archpsyc.1982.04290070025006.
26. Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE. Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry (1995) 52:1061-70. doi:10.1001/archpsyc.1995.03950240079013.
27. Bogerts B, Lieberman JA, Ashtari M, Bilder RM, Degreef G, Lerner G, et al. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry (1993) 33:236-46. doi:10.1016/0006-3223(93)90289-P.
28. Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry (1993) 150:59-65.
29. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, et al. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry (1998) 55:145-52. doi:10.1001/archpsyc.55.2.145.
30. Gur RE, Turetsky BI, Bilker WB, Gur RC. Reduced gray matter volume in schizophrenia. Arch Gen Psychiatry (1999) 56:905-11. doi:10.1001/archpsyc.56.10.905.
31. Schröder J, Buchsbaum MS, Siegel BV, Geider FJ, Niethammer R. Structural and functional correlates of subsyndromes in chronic schizophrenia. Psychopathology (1995) 28:38-45. doi:10.1159/000284898.
32. Schröder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, et al. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res (1996) 19:41-53. doi:10.1016/0920-9964(95)00043-7.
33. Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry (2002) 159:227-37. doi:10.1176/appi.ajp.159.2.227.
34. Heckers S, GoffD, Schacter DL, Savage CR, Fischman AJ, Alpert NM, et al. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatry (1999) 56:1117-23. doi:10.1001/archpsyc.56.12.1117.
35. Menon V, Anagnoson RT, Mathalon DH, Glover GH, Pfefferbaum A. Functional neuroanatomy of auditory working memory in schizophrenia: relation to positive and negative symptoms. Neuroimage (2001) 13:433-46. doi:10.1006/nimg.2000.0699.
36. Perlstein WM, Carter CS, Noll DC, Cohen JD. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry (2001) 158:1105-13. doi:10.1176/appi.ajp.158.7.1105.
37. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry (1992) 49:522-30. doi:10.1001/archpsyc.1992.01820070016003.
38. Ebmeier KP, Blackwood DH, Murray C, Souza V, Walker M, Dougall N, et al. Single-photon emission computed tomography with 99mTc-exametazime in unmedicated schizophrenic patients. Biol Psychiatry (1993) 33:487-95. doi:10.1016/0006-3223(93)90002-U.
39. Kawasaki Y, Maeda Y, Sakai N, Higashima M, Yamaguchi N, Koshino Y, et al. Regional cerebral blood flow in patients with schizophrenia: relevance to symptom structures. Psychiatry Res (1996) 67:49-58. doi:10.1016/0925-4927(96)02685-6.
40. Min SK, An SK, Jon DI, Lee JD. Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. Psychiatry Res (1999) 90:159-68. doi:10.1016/S0925-4927(99)00014-1.
41. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage (2006) 29:409-16. doi:10.1016/j.neuroimage.2005.07.051.
42. Simon JJ, Biller A, Walther S, Roesch-Ely D, Stippich C, Weisbrod M, et al. Neural correlates of reward processing in schizophrenia-relationship to apathy and depression. Schizophr Res (2010) 118:154-61. doi:10.1016/j.schres.2009.11.007.
43. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol (2000) 14(1):1-21. doi:10.1615/CritRevNeurobiol.v14.i1.10.
44. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. American Journal of Psychiatry (2003) 160(10):1809-16. doi:10.1176/appi.ajp.160.10.1809.
45. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry (1992) 149(7):890-7.
46. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex (2000) 10(11):1078-92. doi:10.1093/cercor/10.11.1078.
47. Manoach DS, Gollub RL, Benson ES, Searl MM, GoffDC, Halpern E, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry (2000) 48(2):99-109. doi:10.1016/S0006-3223(00)00227-4.
48. Perlstein WM, Dixit NK, Carter CS, Noll DC, Cohen JD. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry (2003) 53(1):25-38. doi:10.1016/S0006-3223(02)01675-X.
49. Tan H-Y, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci U S A (2007) 104:12536-41. doi:10.1073/pnas.0610125104.
50. Henseler I, Falkai P, Gruber O. A systematic fMRI investigation of the brain systems subserving different working memory components in schizophrenia. Eur J Neurosci (2009) 30:693-702. doi:10.1111/j.1460-9568.2009.06850.x.
51. Meyer-Lindenberg A, Olsen R, Kohn P. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry (2005) 62:379-86. doi:10.1001/archpsyc.62.4.379.
52. Henseler I, Falkai P, Gruber O. Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res (2010) 44:364-72. doi:10.1016/j.jpsychires.2009.09.003.
53. Smith EE, Jonides J. Storage and executive processes in the frontal lobes. Science (1999) 283(5408):1657-61. doi:10.1126/science.283.5408.1657.
54. Gruber O, Goschke T. Executive control emerging from dynamic interactions between brain systems mediating language, working memory and attentional processes. Acta Psychol (Amst). (2004) 115(2-3):105-21. doi:10.1016/j.actpsy.2003.12.003.
55. Gruber O, Melcher T, Diekhof EK, Karch S, Falkai P, Goschke T. Brain mechanisms associated with background monitoring of the environment for potentially significant sensory events. Brain Cogn (2009) 69:559-64. doi:10.1016/j.bandc.2008.11.008.
56. Montague PR, Berns GS. Neural economics and the biological substrates of valuation. Neuron (2002) 36(2):265-84. doi:10.1016/S0896-6273(02)00974-1.
57. Cools R, Clark L, Owen AM, Robbins TW. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci (2002) 22(11):4563-7.
58. Kringelbach ML, Rolls ET. Neural correlates of rapid reversal learning in a simple model of human social interaction. Neuroimage (2003) 20(2):1371-83. doi:10.1016/S1053-8119(03)00393-8.
59. O'Doherty J, Winston J, Critchley H, Perrett D, Burt DM, Dolan RJ. Beauty in a smile: the role of medial orbitofrontal cortex in facial attractiveness. Neuropsychologia (2003) 41(2):147-55. doi:10.1016/S0028-3932(02)00145-8.
60. Gruber O, Diekhof EK, Kirchenbauer L, Goschke T. A neural system for evaluating the behavioural relevance of salient events outside the current focus of attention. Brain Res (2010) 1351:212-21. doi:10.1016/j.brainres.2010.06.056.
61. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry (2009) 66:811-22. doi:10.1001/archgenpsychiatry.2009.91.
62. Krabbendam L, O'Daly O, Morley LA, van Os J, Murray RM, Shergill SS. Using the Stroop task to investigate the neural correlates of symptom change in schizophrenia. Br J Psychiatry (2009) 194:373-4. doi:10.1192/bjp.bp.108.055459.
63. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry (2008) 13:267-76. doi:10.1038/sj.mp.4002058.
64. Achim AM, Lepage M. Episodic memory-related activation in schizophrenia: meta-analysis. Br J Psychiatry (2005) 187:500-9. doi:10.1192/bjp.187.6.500.
65. Lesh TA, Niendam TA, Minzenberg MJ, Carter CS. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology (2011) 36:316-38. doi:10.1038/npp.2010.156.
66. Li H, Chan RCK, McAlonan GM, Gong Q. Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophr Bull (2010) 36:1029-39. doi:10.1093/schbul/sbn190.
67. Brunet-Gouet E, Decety J. Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res (2006) 148:75-92. doi:10.1016/j.pscychresns.2006.05.001.
68. Rasetti R, Mattay VS, Wiedholz LM, Kolachana BS, Hariri AR, Callicott JH, et al. Evidence that altered amygdala activity in schizophrenia is related to clinical state and not genetic risk. Am J Psychiatry (2009) 166:216-25. doi:10.1176/appi.ajp.2008.08020261.
69. Straub RE, Weinberger DR. Schizophrenia genes-famine to feast. Biol Psychiatry (2006) 60:81-3. doi:10.1016/j.biopsych.2006.002.
70. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull (2009) 35(3):549-62. doi:10.1093/schbul/sbp006.
71. Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol (2012) 3:195. doi:10.3389/fphar.2012.00195.
72. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med (2006) 12:1016-22. doi:10.1038/nm1478.
73. O'Donnell P, Grace AA. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull (1998) 24(2):267-83. doi:10.1093/oxfordjournals.schbul.a033325.
74. Tost H, Meyer-Lindenberg A. Dopamine-glutamate interactions: a neural convergence mechanism of common schizophrenia risk variants. Biol Psychiatry (2011) 69(10):912-3. doi:10.1016/j.biopsych.2011.03.013.
75. Blaha CD, Yang CR, Floresco SB, Barr AM, Phillips AG. Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor-mediated changes in dopamine efflux in the rat nucleus accumbens. Eur J Neurosci (1997) 9:902-11. doi:10.1111/j.1460-9568.1997.tb01441.x.
76. Legault M, Wise RA. Injections of N-methyl-D-aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Synapse (1999) 31:241-9. doi:10.1002/(SICI)1098-2396(19990315)31:4<241::AID-SYN1>3.0.CO;2-#.
77. Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administration alters proteomic and metabolomic markers of hippocampal glutamatergic transmission. Neuropsychopharmacology (2012) 37:319-20. doi:10.1038/npp.2011.255.
78. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci (2007) 27:11424-30. doi:10.1523/JNEUROSCI.2847-07.2007.
79. Marsman A, van den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, HulshoffPol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull (2013) 39(1):120-9. doi:10.1093/schbul/sbr069.
80. Poels EMP, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry (2013) 19(1):20-9. doi:10.1038/mp.2013.136.
81. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2012) 69:449-59. doi:10.1001/archgenpsychiatry.2011.1519.
82. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry (2002) 159:1944-6. doi:10.1176/appi.ajp.159.11.1944.
83. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1997) 54:959-65. doi:10.1001/archpsyc.1997.01830220085012.
84. Théberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry (2007) 191:325-34. doi:10.1192/bjp.bp.106.033670.
85. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology (2012) 37:2515-21. doi:10.1038/npp.2012.113.
86. Ohrmann P, Kugel H, Bauer J, Siegmund A, Kölkebeck K, Suslow T, et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr Res (2008) 106:156-63. doi:10.1016/j.schres.2008.08.005.
87. Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry (2011) 69:19-27. doi:10.1016/j.biopsych.2010.08.024.
88. Ongür D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 64:718-26. doi:10.1016/j.biopsych.2008.05.014.
89. Wood SJ, Yücel M, Wellard RM, Harrison BJ, Clarke K, Fornito A, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res (2007) 94:328-31. doi:10.1016/j.schres.2007.05.008.
90. Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC. Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology (2012) 37:2635-42. doi:10.1038/npp.2012.126.
91. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, et al. 1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry (2010) 15:629-36. doi:10.1038/mp.2009.121.
92. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2010) 68:625-33. doi:10.1016/j.biopsych.2010.04.013.
93. de la Fuente-Sandoval C, León-Ortiz P, Favila R, Stephano S, Mamo D, Ramírez-Bermúdez J, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology (2011) 36:1781-91. doi:10.1038/npp.2011.65.
94. de la Fuente-Sandoval C, León-Ortiz P, Azcárraga M, Stephano S, Favila R, Díaz-Galvis L, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry (2013) 70:1057-66. doi:10.1001/jamapsychiatry.2013.289.
95. Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K, et al. Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat (2012) 8:119-22. doi:10.2147/NDT.S25582.
96. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val(108/158) Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A (2001) 98:6917-22. doi:10.1073/pnas.111134598.
97. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci (2005) 8:594-6. doi:10.1038/nn1438.
98. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci (2006) 7:818-27. doi:10.1038/nrn1993.
99. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, et al. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry (2006) 11:867-77. doi:10.1038/sj.mp.4001860.
100. Nixon DC, Prust MJ, Sambataro F, Tan H-Y, Mattay VS, Weinberger DR, et al. Interactive effects of DAOA (G72) and catechol-O-methyltransferase on neurophysiology in prefrontal cortex. Biol Psychiatry (2011) 69:1006-8. doi:10.1016/j.biopsych.2010.10.031.
101. Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF, et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet (2007) 120:889-906. doi:10.1007/s00439-006-0257-3.
102. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 40:1053-5. doi:10.1038/ng.201.
103. Ferreira MAR, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 40:1056-8. doi:10.1038/ng.209.
104. Esslinger C, Walter H, Kirsch P, Erk S, Schnell K, Arnold C, et al. Neural mechanisms of a genome-wide supported psychosis variant. Science (2009) 324:605. doi:10.1126/science.1167768.
105. Paulus FM, Krach S, Bedenbender J, Pyka M, Sommer J, Krug A, et al. Partial support for ZNF804A genotype-dependent alterations in prefrontal connectivity. Hum Brain Mapp (2013) 34:304-13. doi:10.1002/hbm.21434.
106. Rasetti R, Sambataro F, Chen Q, Callicott JH, Mattay VS, Weinberger DR. Altered cortical network dynamics a potential intermediate phenotype for schizophrenia and association with ZNF804A RID E-3426-2010. Arch Gen Psychiatry (2011) 68:1207-17. doi:10.1001/archgenpsychiatry.2011.103.
107. Erk S, Meyer-Lindenberg A, Schnell K, Opitz von Boberfeld C, Esslinger C, Kirsch P, et al. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch Gen Psychiatry (2010) 67:803-11. doi:10.1001/archgenpsychiatry.2010.94.
108. Bigos KL, Mattay VS, Callicott JH, Straub RE, Vakkalanka R, Kolachana B, et al. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch Gen Psychiatry (2010) 67:939-45. doi:10.1001/archgenpsychiatry.2010.96.
109. Wessa M, Linke J, Witt SH, Nieratschker V, Esslinger C, Kirsch P, et al. The CACNA1C risk variant for bipolar disorder influences limbic activity. Mol Psychiatry (2010) 15:1126-7. doi:10.1038/mp.2009.103.
110. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res (2010) 122:1-23. doi:10.1016/j.schres.2010.05.025.
111. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2009) 373:31-41. doi:10.1016/S0140-6736(08)61764-X.
112. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother (2010) 10:43-57. doi:10.1586/ern.09.143.
113. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 263(5):367-77. doi:10.1007/s00406-013-0399-y.
114. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 62:405-96. doi:10.1124/pr.109.002451.
115. Shepherd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Annu Rev Cell Dev Biol (2007) 23:613-43. doi:10.1146/annurev.cellbio.23.090506.123516.
116. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 325:529-31. doi:10.1038/325529a0.
117. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev (2006) (2):CD003730. doi:10.1002/14651858.CD003730.pub2.
118. Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des (2010) 16:522-37. doi:10.2174/138161210790361452.
119. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 164:1593-602. doi:10.1176/appi.ajp.2007.06081358.
120. GoffDC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr Bull (2012) 38:936-41. doi:10.1093/schbul/sbs012.
121. GoffDC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res (2008) 106:320-7. doi:10.1016/j.schres.2008.08.012.
122. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 44:1081-9. doi:10.1016/S0006-3223(98)00279-0.
123. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry (2005) 57:577-85. doi:10.1016/j.biopsych.2004.12.037.
124. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 121:125-30. doi:10.1016/j.schres.2010.05.012.
125. Lane H-Y, Lin C-H, Huang Y-J, Liao C-H, Chang Y-C, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol (2010) 13:451-60. doi:10.1017/S1461145709990939.
126. Javitt DC. Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol (2012) 213:367-99. doi:10.1007/978-3-642-25758-2_12.
127. Javitt DC, Zukin SR, Heresco-levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull (2012) 38:958-66. doi:10.1093/schbul/sbs069.
128. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2012) 12(457):910-4. doi:10.1038/nature07762.
129. Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin- 2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyletho xy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem (2010) 53:4603-14. doi:10.1021/jm100210p.
130. Alberati D, Moreau J-L, Lengyel J, Hauser N, Mory R, Borroni E, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology (2012) 62:1152-61. doi:10.1016/j.neuropharm.2011.11.008.
131. Roche Global Web Site. Phase II Study with First-in-Class Investigational Drug Demonstrates Improvement in Negative Symptoms in Patients with Schizophrenia. (2010). Available from: http://www.roche.com/investors/ir_update/inv-update-2010-12-06b.htm.
132. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 361:31-9. doi:10.1038/361031a0.
133. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther (1999) 24:369-74. doi:10.1046/j.1365-2710.1999.00238.x.
134. GoffDC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol (2001) 21:484-7. doi:10.1097/00004714-200110000-00005.
135. GoffDC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, et al. A placebo-controlled add-on trial of the ampakine CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology (2008) 33:465-72. doi:10.1038/sj.npp.1301444.
136. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 17(8):2921-7.
137. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol (2012) 213:267-95. doi:10.1007/978-3-642-25758-2_10.
138. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol (2010) 50:295-322. doi:10.1146/annurev.pharmtox.011008.145533.
139. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 13(9):1102-7. doi:10.1038/nm1007-1264.
140. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol (2011) 31(3):349-55. doi:10.1097/JCP.0b013e318218dcd5.
141. Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry (2013) 13(1):143. doi:10.1186/1471-244X-13-143.
142. Stauffer VL, Ayan-Oshodi M, Wondmagegnehu ET, Witcher J, Shen T, Yuen ESM, et al. A phase 1B study investigating the potential interaction between LY2140023 and second generation antipsychotics in subjects with schizophrenia or schizoaffective disorder. Schizophr Res (2012) 136:S169-70. doi:10.1016/S0920-9964(12)70533-9.
143. Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res (2013) 150:434-41. doi:10.1016/j.schres.2013.08.020.
144. Addex Therapeutics. Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients. Addex Therapeutics Press Release (2012). Available from: http://www.addextherapeutics.com/about/about-addex/.
145. Kent JM, Anghelescu IG, Kezic I, Daly E, Ceusters M, De Smedt H, et al. Safety, tolerability and potential therapeutic efficacy of a novel glutamate modulator as adjunctive treatment in patients with schizophrenia. APA 2013 Annual Meeting. San Francisco (2013).
146. Kraepelin E. Psychiatrie-Ein Lehrbuch für Studierende und ärzte. 5th ed. Leipzig: Barth (1896).